Results 11 to 20 of about 2,904 (163)
JCI Insight, 2023 Hepatocellular carcinoma (HCC) is the most common lethal form of liver cancer. Apart from surgical removal and transplantation, other treatments have not yet been well established for patients with HCC.
Gang Li +10 more
doaj +3 more sources
Атеротромбоз, 2018 Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2].
D. A. Sychev +8 more
doaj +5 more sources
Pharmacogenomics and Personalized Medicine, 2021 Yue Liu,1,* Chenguang Yang,2,* Wenyuan Qi,1 Zuowei Pei,2 Wei Xue,1 Huolan Zhu,2 Min Dong,2 Ying Guo,2 Duanduan Cong,1 Fang Wang2 1Clinical Trial Center, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Science ...
Liu Y +9 more
doaj +4 more sources
Pharmacogenomics and Personalized Medicine, 2022 Marta H Hernandez1,2 *, Valentin Bote3 *, Alexandre Serra-LLovich,1 Marc Cendros,1,4 Juliana Salazar,5 Conxita Mestres,2 Silvina Guijarro,3 Aida Alvarez,3 Cristina Lamborena,3 Iria Mendez,3 Bernardo Sanchez,3 Amaia Hervas,3 Maria J Arranz1,2 ...
Hernandez MH +12 more
doaj +6 more sources
Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population [PDF]
Caspian Journal of Internal MedicineBackground: Allelic variants of genes encoding enzymes of the esterase system (CES1) and P-glycoprotein (ABCB1) can change the metabolism and pharmacokinetics of dabigatran.
Ayan Abdrakhmanov +10 more
doaj +3 more sources
Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation [PDF]
The FASEB Journal, 2016 Sacubitril was recently approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure with reduced ejection fraction. As a prodrug, sacubitril must be metabolized (hydrolyzed) to its active metabolite sacubitrilat (LBQ657) to exert its intended therapeutic effects.
Jian, Shi +5 more
+9 more sources
Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation. [PDF]
Mol PharmClopidogrel, a frequently used prodrug, is converted to its active metabolite through the intermediate 2-oxo-clopidogrel by cytochrome P450 (CYP) enzymes, which accounts for only 5%-15% of its metabolism. Majority of the clopidogrel dose (85%-90%) is extensively hydrolyzed to its inactive metabolite, clopidogrel carboxylic acid by carboxylesterase 1 ...
Subash S +8 more
europepmc +3 more sources
Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels. [PDF]
PLoS ONE, 2014 Metabolic syndrome, characterized by obesity, hyperglycemia, dyslipidemia and hypertension, increases the risks for cardiovascular disease, diabetes and stroke.
Jiesi Xu +6 more
doaj +1 more source
Scientific Reports, 2021 A recent genome-wide copy number variations (CNVs) scan identified a 16q12.2 deletion that included the carboxylesterase 1 (CES1) gene, which is important in the metabolism of fatty acids and cholesterol.
Bing bing Chen +8 more
doaj +1 more source
Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function. [PDF]
PLoS ONE, 2013 CONTEXT AND AIMS: Carboxylesterase 1 (CES1) appears to play an important role in the control of the metabolism of triglycerides and cholesterol in adipocytes and other cell types including hepatocytes.
Martin Friedrichsen +5 more
doaj +1 more source